false --12-31 Q2 0000722313 0000722313 2025-01-01 2025-06-30 0000722313 2025-07-31 0000722313 2025-04-01 2025-06-30 0000722313 2024-04-01 2024-06-30 0000722313 2024-01-01 2024-06-30 0000722313 2025-06-30 0000722313 2024-12-31 0000722313 2023-12-31 0000722313 2024-06-30 0000722313 us-gaap:PreferredStockMember 2024-03-31 0000722313 us-gaap:CommonStockMember 2024-03-31 0000722313 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000722313 us-gaap:RetainedEarningsMember 2024-03-31 0000722313 2024-03-31 0000722313 us-gaap:PreferredStockMember 2025-03-31 0000722313 us-gaap:CommonStockMember 2025-03-31 0000722313 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000722313 us-gaap:RetainedEarningsMember 2025-03-31 0000722313 2025-03-31 0000722313 us-gaap:PreferredStockMember 2023-12-31 0000722313 us-gaap:CommonStockMember 2023-12-31 0000722313 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000722313 us-gaap:RetainedEarningsMember 2023-12-31 0000722313 us-gaap:PreferredStockMember 2024-12-31 0000722313 us-gaap:CommonStockMember 2024-12-31 0000722313 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000722313 us-gaap:RetainedEarningsMember 2024-12-31 0000722313 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000722313 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000722313 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000722313 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000722313 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0000722313 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000722313 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0000722313 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0000722313 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000722313 us-gaap:PreferredStockMember 2025-01-01 2025-06-30 0000722313 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-06-30 0000722313 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0000722313 us-gaap:PreferredStockMember 2024-06-30 0000722313 us-gaap:CommonStockMember 2024-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000722313 us-gaap:RetainedEarningsMember 2024-06-30 0000722313 us-gaap:PreferredStockMember 2025-06-30 0000722313 us-gaap:CommonStockMember 2025-06-30 0000722313 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000722313 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000722313 us-gaap:RetainedEarningsMember 2025-06-30 0000722313 us-gaap:PatentsMember 2024-12-31 0000722313 us-gaap:PatentsMember 2025-01-01 2025-06-30 0000722313 us-gaap:PatentsMember 2025-06-30 0000722313 NSYS:PatentsReceivedMember 2025-06-30 0000722313 NSYS:PatentsInProcessMember 2025-06-30 0000722313 us-gaap:SubsequentEventMember NSYS:BlueEarthFacilityMember 2025-07-01 2025-07-31 0000722313 country:US 2025-01-01 2025-06-30 0000722313 country:CN 2025-01-01 2025-06-30 0000722313 country:CN 2025-06-30 0000722313 country:MX 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember srt:AmericasMember us-gaap:GeographicConcentrationRiskMember 2025-04-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember srt:AmericasMember us-gaap:GeographicConcentrationRiskMember 2025-01-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember srt:AmericasMember us-gaap:GeographicConcentrationRiskMember 2024-04-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember srt:AmericasMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember 2025-01-01 2025-06-30 0000722313 us-gaap:AccountsReceivableMember 2025-01-01 2025-06-30 0000722313 NSYS:ContractAssetMember 2025-01-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2025-04-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2024-04-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2025-01-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2024-01-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerBMember 2025-04-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerBMember 2024-04-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerBMember 2025-01-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerBMember 2024-01-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2025-04-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2024-04-01 2024-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2025-01-01 2025-06-30 0000722313 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2024-01-01 2024-06-30 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2025-01-01 2025-06-30 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2024-01-01 2024-12-31 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerCMember 2025-01-01 2025-06-30 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerCMember 2024-01-01 2024-12-31 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2025-01-01 2025-06-30 0000722313 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2024-01-01 2024-12-31 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2025-01-01 2025-06-30 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerAMember 2024-01-01 2024-12-31 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerDMember 2025-01-01 2025-06-30 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerDMember 2024-01-01 2024-12-31 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2025-01-01 2025-06-30 0000722313 NSYS:ContractAssetMember us-gaap:CustomerConcentrationRiskMember NSYS:CustomerMember 2024-01-01 2024-12-31 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalDeviceMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalDeviceMember 2025-04-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalDeviceMember 2025-04-01 2025-06-30 0000722313 NSYS:MedicalDeviceMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalImagingMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalImagingMember 2025-04-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalImagingMember 2025-04-01 2025-06-30 0000722313 NSYS:MedicalImagingMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:IndustrialMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:IndustrialMember 2025-04-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:IndustrialMember 2025-04-01 2025-06-30 0000722313 NSYS:IndustrialMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:AerospaceAndDefenseMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:AerospaceAndDefenseMember 2025-04-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:AerospaceAndDefenseMember 2025-04-01 2025-06-30 0000722313 NSYS:AerospaceAndDefenseMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember 2025-04-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember 2025-04-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalDeviceMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalDeviceMember 2024-04-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalDeviceMember 2024-04-01 2024-06-30 0000722313 NSYS:MedicalDeviceMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalImagingMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalImagingMember 2024-04-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalImagingMember 2024-04-01 2024-06-30 0000722313 NSYS:MedicalImagingMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:IndustrialMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:IndustrialMember 2024-04-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:IndustrialMember 2024-04-01 2024-06-30 0000722313 NSYS:IndustrialMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:AerospaceAndDefenseMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:AerospaceAndDefenseMember 2024-04-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:AerospaceAndDefenseMember 2024-04-01 2024-06-30 0000722313 NSYS:AerospaceAndDefenseMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember 2024-04-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember 2024-04-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalDeviceMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalDeviceMember 2025-01-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalDeviceMember 2025-01-01 2025-06-30 0000722313 NSYS:MedicalDeviceMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalImagingMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalImagingMember 2025-01-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalImagingMember 2025-01-01 2025-06-30 0000722313 NSYS:MedicalImagingMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:IndustrialMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:IndustrialMember 2025-01-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:IndustrialMember 2025-01-01 2025-06-30 0000722313 NSYS:IndustrialMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:AerospaceAndDefenseMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:AerospaceAndDefenseMember 2025-01-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:AerospaceAndDefenseMember 2025-01-01 2025-06-30 0000722313 NSYS:AerospaceAndDefenseMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-06-30 0000722313 NSYS:NoncashConsiderationMember 2025-01-01 2025-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalDeviceMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalDeviceMember 2024-01-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalDeviceMember 2024-01-01 2024-06-30 0000722313 NSYS:MedicalDeviceMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:MedicalImagingMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:MedicalImagingMember 2024-01-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:MedicalImagingMember 2024-01-01 2024-06-30 0000722313 NSYS:MedicalImagingMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:IndustrialMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:IndustrialMember 2024-01-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:IndustrialMember 2024-01-01 2024-06-30 0000722313 NSYS:IndustrialMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember NSYS:AerospaceAndDefenseMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember NSYS:AerospaceAndDefenseMember 2024-01-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember NSYS:AerospaceAndDefenseMember 2024-01-01 2024-06-30 0000722313 NSYS:AerospaceAndDefenseMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredOverTimeMember 2024-01-01 2024-06-30 0000722313 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-06-30 0000722313 NSYS:NoncashConsiderationMember 2024-01-01 2024-06-30 0000722313 us-gaap:LineOfCreditMember NSYS:SeniorSecuredRevolvingLineOfCreditMember NSYS:BankOfAmericaMember 2024-02-29 0000722313 2025-05-14 2025-05-14 0000722313 us-gaap:LineOfCreditMember NSYS:CreditAgreementMember NSYS:BankOfAmericaMember 2025-01-01 2025-06-30 0000722313 us-gaap:LineOfCreditMember NSYS:CreditAgreementMember NSYS:BankOfAmericaMember 2024-01-01 2024-12-31 0000722313 us-gaap:LineOfCreditMember NSYS:CreditAgreementMember NSYS:BankOfAmericaMember 2025-06-30 0000722313 us-gaap:LineOfCreditMember NSYS:CreditAgreementMember NSYS:BankOfAmericaMember 2024-12-31 0000722313 NSYS:CreditAgreementMember NSYS:BankOfAmericaMember 2025-06-30 0000722313 srt:MinimumMember 2025-06-30 0000722313 srt:MaximumMember 2025-06-30 0000722313 us-gaap:GeneralAndAdministrativeExpenseMember 2025-04-01 2025-06-30 0000722313 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0000722313 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-06-30 0000722313 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0000722313 NSYS:TwoThousandSeventeenStockIncentivePlanMember 2025-06-30 0000722313 NSYS:ServiceBasedStockOptionsMember 2025-04-01 2025-06-30 0000722313 NSYS:ServiceBasedStockOptionsMember 2025-01-01 2025-06-30 0000722313 NSYS:ServiceBasedStockOptionsMember 2024-04-01 2024-06-30 0000722313 NSYS:ServiceBasedStockOptionsMember 2024-01-01 2024-06-30 0000722313 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0000722313 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0000722313 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0000722313 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0000722313 us-gaap:EmployeeStockOptionMember 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember NSYS:TwoThousandSeventeenStockIncentivePlanMember 2025-04-01 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember NSYS:TwoThousandSeventeenStockIncentivePlanMember 2024-04-01 2024-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember NSYS:TwoThousandSeventeenStockIncentivePlanMember 2025-01-01 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember NSYS:TwoThousandSeventeenStockIncentivePlanMember 2024-01-01 2024-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember NSYS:TwoThousandSeventeenStockIncentivePlanMember 2025-06-30 0000722313 2023-01-01 2023-12-31 0000722313 2024-01-01 2024-12-31 0000722313 us-gaap:RestrictedStockMember 2023-12-31 0000722313 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000722313 us-gaap:RestrictedStockMember 2024-01-01 2024-06-30 0000722313 us-gaap:RestrictedStockMember 2024-06-30 0000722313 us-gaap:RestrictedStockMember 2024-12-31 0000722313 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0000722313 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0000722313 us-gaap:RestrictedStockMember 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000722313 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0000722313 country:US 2025-04-01 2025-06-30 0000722313 country:US 2024-04-01 2024-06-30 0000722313 country:US 2024-01-01 2024-06-30 0000722313 country:MX 2025-04-01 2025-06-30 0000722313 country:MX 2024-04-01 2024-06-30 0000722313 country:MX 2025-01-01 2025-06-30 0000722313 country:MX 2024-01-01 2024-06-30 0000722313 country:CN 2025-04-01 2025-06-30 0000722313 country:CN 2024-04-01 2024-06-30 0000722313 country:CN 2024-01-01 2024-06-30 0000722313 country:US 2024-01-01 2024-12-31 0000722313 country:MX 2024-01-01 2024-12-31 0000722313 country:CN 2024-01-01 2024-12-31 0000722313 NSYS:FacilityConsolidationMember 2024-12-31 0000722313 NSYS:WorkforceReductionsMember 2024-12-31 0000722313 NSYS:FacilityConsolidationMember 2025-01-01 2025-06-30 0000722313 NSYS:WorkforceReductionsMember 2025-01-01 2025-06-30 0000722313 NSYS:FacilityConsolidationMember 2025-06-30 0000722313 NSYS:WorkforceReductionsMember 2025-06-30 0000722313 NSYS:FacilityConsolidationMember 2023-12-31 0000722313 NSYS:FacilityConsolidationMember 2024-01-01 2024-06-30 0000722313 NSYS:FacilityConsolidationMember 2024-06-30 0000722313 NSYS:AbilitechMedicalIncMember 2023-12-31 0000722313 NSYS:AbilitechMedicalIncMember 2024-12-31 0000722313 NSYS:AbilitechMedicalIncMember NSYS:MarpeTechnologiesLTDMember srt:MaximumMember 2025-06-30 0000722313 NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember 2025-06-30 0000722313 NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember NSYS:MarpeTechnologiesLTDMember 2025-06-30 0000722313 NSYS:MarpeTechnologiesLTDMember NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember 2025-04-01 2025-06-30 0000722313 NSYS:MarpeTechnologiesLTDMember NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember 2025-01-01 2025-06-30 0000722313 NSYS:MarpeTechnologiesLTDMember NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember 2024-04-01 2024-06-30 0000722313 NSYS:MarpeTechnologiesLTDMember NSYS:AgreementBetweenTheBIRDFoundationTheCompanyAndMarpeTechnologiesLTDMember 2024-01-01 2024-06-30 0000722313 NSYS:MarpeTechnologiesLTDMember 2025-06-30 0000722313 us-gaap:SubsequentEventMember NSYS:BlueEarthFacilityMember 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure NSYS:Integer

 

 

 

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D. C. 20549

 

FORM10-Q

 

(MarkOne)

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Forthe quarterly period ended June 30, 2025

 

OR

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Forthe transition period from to

 

NORTECHSYSTEMS INCORPORATED

 

Commissionfile number 0-13257

 

Stateof Incorporation: Minnesota

 

IRSEmployer Identification No. 41-1681094

 

ExecutiveOffices: 7550 Meridian Circle N., Suite # 150, Maple Grove, MN 55369

 

Telephonenumber: (952) 345-2244

 

Securitiesregistered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.01 per share   NSYS   NASDAQ Capital Market

 

Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes No

 

Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit and post such files). Yes No

 

Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer   Accelerated Filer ☐
Non-accelerated Filer   Smaller Reporting Company
Emerging growth company    

 

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

Numberof shares of $0.01 par value common stock outstanding as of July 31, 2025 was 2,786,134.

 

 

 

 

 

 

TABLEOF CONTENTS

 

  PAGE
   
PART I – FINANCIAL INFORMATION  
   
Item 1 - Financial Statements  
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) 3
Condensed Consolidated Balance Sheets 4
Condensed Consolidated Statements of Cash Flows 5-6
Condensed Consolidated Statements of Shareholders’ Equity 7
Notes to Condensed Consolidated Financial Statements 8-17
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
Item 3 - Quantitative and Qualitative Disclosures About Market Risk 24
Item 4 - Controls and Procedures 24
   
PART II – OTHER INFORMATION  
   
Item 1 - Legal Proceedings 25
Item 1A. - Risk Factors 25
Item 2 - Unregistered Sales of Equity Securities, Use of Proceeds 25
Item 3 - Defaults on Senior Securities 25
Item 4 - Mine Safety Disclosures 25
Item 5 - Other Information 25
Item 6 - Exhibits 25
SIGNATURES 26

 

2

 

 

PARTI

 

ITEM1. FINANCIAL STATEMENTS

 

NORTECHSYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSEDCONSOLIDATED STATEMENTS OF OPERATIONS

ANDCOMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

(INTHOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

 

   2025   2024   2025   2024 
   THREE MONTHS ENDED   SIX MONTHS ENDED 
   JUNE 30,   JUNE 30, 
   2025   2024   2025   2024 
                 
Net sales  $30,675   $33,891   $57,570   $68,106 
Cost of goods sold   25,838    29,274    49,655    58,041 
Gross profit   4,837    4,617    7,915    10,065 
Operating expenses:                    
Selling   1,204    909    2,388    1,714 
General and administrative   

2,589

    2,982    

5,504

    6,152 
Research and development   302    291    628    609 
Restructuring charges   -    91    266    91 
Total operating expenses   4,095    4,273    

8,786

    8,566 
Income (loss) from operations   742    344    (871)   1,499 
Other expense:                    
Interest expense   (257)   (165)   (471)   (332)
Income (loss) before income taxes   485    179    (1,342)   1,167 
Income tax expense (benefit)    172   22    (339)   245 
Net income (loss)  $

313

   $157   $(1,003)  $922 
                     
Net income (loss) per common share:                    
Basic (in dollars per share)  $0.12   $0.06   $(0.36)  $0.34 
Weighted average number of common shares outstanding - basic (in shares)   2,773,598    2,760,052    2,767,263    2,751,330 
Diluted (in dollars per share)  $0.12   $0.05   $(0.36)  $0.32 
Weighted average number of common shares outstanding - diluted (in shares)   2,954,765    2,935,671    2,767,263    2,922,113 
                     
Other comprehensive income (loss)                    
Foreign currency translation   

124

    (175)   

130

    (358)
Comprehensive income (loss), net of tax  $

437

   $(18)  $

(873

)  $564 

 

SeeAccompanying Notes to Condensed Consolidated Financial Statements.

 

3

 

 

NORTECHSYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSEDCONSOLIDATED BALANCE SHEETS

ASOF JUNE 30, 2025 AND DECEMBER 31, 2024

(UNAUDITED)

(INTHOUSANDS, EXCEPT SHARE DATA)

 

  

JUNE 30,

2025

  

DECEMBER 31,

2024

 
ASSETS          
Current assets:          
Cash  $652   $916 
Accounts receivable, less allowances of $206 and $196, respectively   17,810    14,875 
Inventories, net   18,628    21,638 
Contract assets   14,984    13,792 
Assets held for sale   495    - 
Prepaid assets and other assets   

5,749

    

4,094

 
Total current assets   

58,318

    55,315 
Property and equipment, net   5,443    6,232 
Operating lease assets, net   7,563    8,139 
Deferred tax assets   3,275    2,575 
Other intangible assets, net   165    174 
Other assets   

61

    

-

 
Total assets  $

74,825

   $72,435 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $11,931   $11,582 
Accrued payroll and commissions   1,752    1,841 
Customer deposits   5,176    5,140 
Current portion of operating lease obligations   1,237    1,175 
Current portion of finance lease obligations   229    143 
Notes payable   -    344 
Other accrued liabilities   

1,283

    1,203 
Total current liabilities   

21,608

    21,428 
Long-term liabilities:          
Long-term line of credit   

11,615

    8,634 
Long-term operating lease obligations, net of current portion   

7,145

    7,773 
Long-term finance lease obligations, net of current portion   781    311 
Other long-term liabilities   

288

    284 
Total long-term liabilities   

19,829

    17,002 
Total liabilities   

41,437

    38,430 
Shareholders’ equity:          
Preferred stock, $1 par value; 1,000,000 shares authorized; 250,000 shares issued and outstanding   250    250 
Common stock - $0.01 par value; 9,000,000 shares authorized; 2,780,134 and 2,760,793 shares issued and outstanding, respectively   28    28 
Additional paid-in capital   17,585    17,329 
Accumulated other comprehensive loss   

(847

)   (977)
Retained earnings   

16,372

    17,375 
Total shareholders’ equity   

33,388

    34,005 
Total liabilities and shareholders’ equity  $

74,825

   $72,435 

 

SeeAccompanying Notes to Condensed Consolidated Financial Statements.

 

4

 

 

NORTECHSYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSEDCONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(INTHOUSANDS)

 

   2025   2024 
   SIX MONTHS ENDED 
   JUNE 30, 
   2025   2024 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net (loss) income  $

(1,003

)  $922 
Adjustments to reconcile net (loss) income to net cash used in operating activities:          
Depreciation and amortization   

678

    

966

 
Compensation on stock-based awards   235    206 
Deferred taxes   (700)   - 
Change in accounts receivable allowance   10    (88)
Change in inventory reserves   351    113 
Other, net   -    (59)
Changes in current operating assets and liabilities:          
Accounts receivable   

(2,842

)   1,690 
Inventories   

2,714

    (1,288)
Contract assets   (1,192)   (476)
Prepaid expenses and other assets   

(1,647

)   (531)
Accounts payable   

295

    (2,546)
Accrued payroll and commissions   (94)   (1,516)
Customer deposits   36    1,385 
Other accrued liabilities   

386

   (236)
Net cash used in operating activities   

(2,773

)   (1,458)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Proceeds from sale of property and equipment   9    9 
Purchases of property and equipment   

(367

)   (1,020)
Net cash used in investing activities   

(358

)   (1,011)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from line of credit   51,405    68,323 
Payments to line of credit   (48,485)   (65,809)
Principal payments on financing leases   

(85

)   (202)
Stock option exercises   23    31 
Net cash provided by financing activities   

2,858

    2,343 
           
Effect of exchange rate changes on cash   9   (7)
           
Net change in cash   (264)   (133)
Cash - beginning of period   916    1,675 
Cash - end of period  $652   $1,542 

 

5

 

 

NORTECHSYSTEMS INCORPORATED AND SUBSIDIARIES

CONDENSEDCONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(INTHOUSANDS)

 

   SIX MONTHS ENDED 
   JUNE 30, 
   2025   2024 
         
Supplemental disclosure of cash flow information:          
Cash paid for interest  $470   $307 
Cash paid for income taxes  $

389

   $279 
           
Supplemental noncash investing and financing activities:          
Property and equipment purchases in accounts payable  $27   $75 
Conversion of notes payable to finance leases  $637   $- 
Operating lease assets acquired under operating leases  $-   $1,923 

 

SeeAccompanying Notes to Condensed Consolidated Financial Statements.

 

6

 

 

NORTECHSYSTEMS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

(INTHOUSANDS)

 

   Shares   Amount   Shares   Amount   Capital   Loss   Earnings   Equity 
                       Accumulated         
                   Additional   Other       Total 
   Preferred Stock   Common Stock   Paid-In   Comprehensive   Retained   Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Loss   Earnings   Equity 
Balance as of March 31, 2024   250   $250    2,755   $     27   $17,009   $         (715)  $19,435   $36,006 
Net income   -    -    -    -    -    -    157    157 
Foreign currency translation adjustment   -    -    -    -    -    (175)   -    (175)
Compensation on stock-based awards   -    -    -    -    126    -    -    126 
Issuance for stock-based awards   -    -    7    1    30    -    -    31 
Balance as of June 30, 2024   250   $250    2,762   $28   $17,165   $(890)  $19,592   $36,145 
                                         
Balance as of March 31, 2025   250   $250    2,761   $28   $17,466   $(971)  $16,059   $32,832 
Net income   -    -    -    -    -    -    

313

    

313

 
Foreign currency translation adjustment   -    -    -    -    -    124    -    124 
Stock option exercises   -    -    19    -    2    -    -    2 
Compensation on stock-based awards   -    -    -    -    117    -    -    117 
Balance as of June 30, 2025   250   $250    2,780   $28   $17,585   $

(847

)  $

16,372

   $

33,388

 
                                         
Balance as of December 31, 2023   250   $250    2,740   $27   $16,929   $(532)  $18,670   $35,344 
Net income   -    -    -    -    -    -    922    922 
Foreign currency translation adjustment   -    -    -    -    -    (358)   -    (358)
Compensation on stock-based awards   -    -    -    -    206    -    -    206 
Issuance for stock-based awards   -    -    22    1    30    -    -    31 
Balance as of June 30, 2024   250   $250    2,762   $28   $17,165   $(890)  $19,592   $36,145 
                                         
Balance as of December 31, 2024   250   $250    2,761   $28   $17,329   $(977)  $17,375   $34,005 
Net loss   -    -    -    -    -    -    (1,003)   

(1,003

)
Foreign currency translation adjustment   -    -    -    -    -    130    -    130 
Stock option exercises   -    -    19    -    21    -    -    21 
Compensation on stock-based awards   -    -    -    -    235    -    -    235 
Balance as of June 30, 2025   250   $250    2,780   $28   $17,585   $(847)  $

16,372

   $

33,388

 

 

SeeAccompanying Notes to Condensed Consolidated Financial Statements.

 

7

 

 

NOTESTO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(DOLLARSIN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(UNAUDITED)

 

NOTE1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basisof Presentation and Principles of Consolidation

 

Theaccompanying unaudited condensed consolidated financial statements for the interim periods have been prepared in accordance with GenerallyAccepted Accounting Principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuantto the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, the Company has omitted footnotedisclosures that would substantially duplicate the disclosures contained in the Company’s audited consolidated financial statements.These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statementsfor the year ended December 31, 2024, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.

 

Thecondensed consolidated financial statements include the accounts of Nortech Systems Incorporated and its wholly owned subsidiaries. Allsignificant intercompany accounts and transactions have been eliminated. All dollar amounts are stated in thousands of U.S. dollars.

 

Useof Estimates

 

Thepreparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reportedamounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financialstatements. Estimates also affect the reported amounts of net sales and expenses during each reporting period. Significant items subjectto estimates and assumptions include the net realizable value reserves for inventories, accounts receivable allowances, realizabilityof deferred tax assets and long-lived asset recovery. Actual results could differ from those estimates.

 

RecentlyIssued New Accounting Standards

 

InNovember 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)2023-07, Segment Reporting Topic (280): Improvements to Reportable Segment Disclosure. The ASU supplements reportable segmentdisclosure requirements, primarily through enhanced disclosures about significant segment expenses. The Company adopted this ASU in thefourth quarter of 2024 and has included related interim reporting disclosures in Note 9 – Segment Information to these condensedconsolidated financial statements.

 

InDecember 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The ASU enhancesthe transparency and decision usefulness of income tax disclosures and is effective for annual periods beginning after December 15, 2024on a prospective basis. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financialstatements disclosures.

 

InNovember 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense DisaggregationDisclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disaggregated expense information inthe notes to the financial statements related to purchases of inventory, employee compensation, depreciation, intangible asset amortizationand selling expenses for each statement of earnings line item that contains those expenses. ASU No. 2024-03 is effective for annual reportingperiods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15,2027. The guidance is to be applied on a prospective basis with the option to apply the standard retrospectively; this ASU allows forearly adoption. The Company is currently evaluating the impact of this ASU on its consolidated financial statements disclosures.

 

In July 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted. The OBBBA makes permanent key elementsof the Tax Cuts and Jobs Act of 2017, including 100% bonus depreciation, domestic research cost expensing and the business interest expenselimitation, among other tax changes. The new legislation has multiple effective dates, with certain provisions effective in 2025 and othersin the future. The Company is currently evaluating the provisions of the new law and the potential effects on the Company’s financialposition, results of operations, and cash flows.

 

8

 

 

Inventories

 

Inventoriesare as follows:

 

   June 30,   December 31, 
   2025   2024 
Raw materials  $18,570   $21,122 
Work in process   802    892 
Finished goods   1,053    1,070 
Reserves   (1,797)   (1,446)
Inventories, net  $18,628   $21,638 

 

OtherIntangible Assets

 

Otherintangible assets as of June 30, 2025 and December 31, 2024 are as follows:

 

   Patents 
Balances as of December 31, 2024  $174 
Amortization   (9)
Balances as of June 30, 2025  $165 

 

Intangibleassets are amortized on a straight-line basis over their estimated useful lives. The weighted average remaining amortization period ofour intangible assets is 4.6 years. Of the patents value as of June 30, 2025, $81 are being amortized and $84 are in process and a patenthas not yet been issued.

 

Amortizationexpense of finite life intangible assets for the three months ended June 30, 2025 and 2024 was $4 and $40, respectively. Amortizationexpense of finite life intangible assets for the six months ended June 30, 2025 and 2024 was $9 and $80, respectively.

 

Asof June 30, 2025, estimated future annual amortization expense (except projects in process) related to these assets is as follows:

 

Year  Amount 
Remainder of 2025  $   10 
2026   18 
2027   18 
2028   18 
2029   12 
Thereafter   5 
Total  $81 

 

Propertyand Equipment

 

Asof June 30, 2025, the Company classified its Blue Earth manufacturing facility and related land as held for sale as the criteria forclassification as held for sale were met. The sale of the Blue Earth facility was completed in July 2025 for $500. The carrying valueof these assets held for sale was $495 as of June 30, 2025 and is classified as a current asset in our condensed consolidated balancesheets.

 

During the second quarter of 2025, in light ofour sustained low stock price, we performed a Step 1 recoverability test in accordance with U.S. GAAP for our long-lived assets.Based on our assessment of undiscounted future cash flows, we concluded that the carrying amounts of our asset group is recoverable,and therefore, no impairment was recognized at this stage.  However, as a result of the sale of our Blue Earth facility in July 2025, we are now closer to meeting the criteria for a Step 2 impairment analysis, which involves estimating the fair value ofthe asset group. If future developments, including changes in market conditions or operational forecasts, result in a decline in fairvalue below carrying amounts, this may lead to the recognition of an impairment loss in subsequent periods. 

 

NOTE2. CONCENTRATION OF CREDIT RISK AND MAJOR CUSTOMERS

 

Financialinstruments that potentially subject us to concentrations of credit risk consist principally of cash, accounts receivable, and contractassets. We maintain our excess cash balances in checking accounts primarily at two financial institutions, one in the United States andone in China. The account in the United States may at times exceed federally insured limits. The Company’s $652 cash balance asof June 30, 2025, included approximately $573 and $5 that was held at banks located in China and Mexico, respectively. We grant creditto customers in the normal course of business and generally do not require collateral on our accounts receivable.

 

Wehave certain customers whose revenue individually represented 10% or more of net sales, or whose accounts receivable balances or contractasset balances individually represented 10% or more of gross accounts receivable.

 

Customerswho represent 10% or more of net sales for the three and six months ended June 30, 2025 and 2024 are as follows:

  

   2025   2024   2025   2024 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2025   2024   2025   2024 
Customer A   31%   26%   31%   25%
Customer B   10%   -%   10%   -%
Total   41%   26%   41%   25%

 

9

 

 

Customerswho represent 10% or more of accounts receivable and contract assets for the period ended June 30, 2025 and December 31, 2024 are asfollows:

 

  

June 30,

2025

  

December 31,

2024

 
   Accounts Receivable 
  

June 30,

2025

  

December 31,

2024

 
Customer A   22%        23%
Customer C   10%   13%
Total   32%   36%

 

  

June 30,

2025

  

December 31,

2024

 
   Contract Assets 
  

June 30,

2025

  

December 31,

2024

 
Customer A   30%        33%
Customer D   16%   12%
Total   46%   45%

 

Exportsales from the U.S. represented approximately 2% of net sales for both the three and six months ended June 30, 2025. Export sales fromthe U.S. represented approximately 3% and 2% of net sales for the three and six months ended June 30, 2024, respectively.

 

NOTE3. NET SALES

 

RevenueRecognition

 

Revenueunder contract manufacturing agreements that was recognized over time, excluding noncash consideration, accounted for 75%of net sales for both the three and six months ended June 30, 2025 and 74%of net sales for both the three and six months ended June 30, 2024.

 

Thefollowing tables summarize our net sales by market for the three and six months ended June 30, 2025 and 2024, respectively:

  

   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
   Three Months Ended June 30, 2025 
   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
Medical Device  $5,049   $2,004   $          497   $7,550 
Medical Imaging   7,490    2,169    5    9,664 
Industrial   6,590    1,799    127    8,516 
Aerospace and Defense   3,975    886    84    4,945 
Total net sales  $23,104   $6,858   $713   $30,675 

 

   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
   Three Months Ended June 30, 2024 
   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
Medical Device(2)  $6,857   $2,129   $       703   $9,689 
Medical Imaging(2)   5,868    2,306    8    8,182 
Industrial   6,163    2,667    555    9,385 
Aerospace and Defense   6,097    494    44    6,635 
Total net sales  $24,985   $7,596   $1,310   $33,891 

 

   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
   Six Months Ended June 30, 2025 
   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
Medical Device  $10,821   $3,734   $      1,065   $15,620 
Medical Imaging   14,198    4,042    12    18,252 
Industrial   11,296    3,931    234    15,461 
Aerospace and Defense   6,757    1,364    116    8,237 
Total net sales  $43,072   $13,071   $1,427   $57,570 

 

   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
   Six Months Ended June 30, 2024 
   Product/ Service Transferred
Over Time
   Product Transferred at Point in Time   Noncash Consideration1   Total Net Sales by Market 
Medical Device(2)  $13,748   $4,648   $      1,497   $19,893 
Medical Imaging(2)   12,041    5,031    11    17,083 
Industrial   13,110    5,014    853    18,977 
Aerospace and Defense   11,301    736    116    12,153 
Total net sales  $50,200   $15,429   $2,477   $68,106 

 

1 Noncash consideration represents material provided by the customer used in the build of the product.
2 Medical, as reported in the prior-year period filing, has been split between Medical Device and Medical Imaging to conform with the current-year presentation.

 

10

 

 

ContractAssets

 

Contractassets, recorded in the condensed consolidated balance sheets, consist of unbilled amounts related to revenue recognized overtime. Significant changes in the contract assets balance during the six months ended June 30, 2025 were as follows:

  

Balance as of December 31, 2024  $13,792 
Increase (decrease) attributed to:     
Amounts transferred over time to contract assets   43,072 
Allowance for current expected credit losses   (1)
Amounts invoiced during the period   (41,879)
Balance outstanding as of June 30, 2025  $14,984 

 

Weexpect substantially all the remaining performance obligations for the contract assets recorded as of June 30, 2025 to be transferredto receivables within 90 days, with any remaining amounts to be transferred within 180 days. We bill our customers upon shipment withpayment terms of up to 120 days.

 

NOTE4. FINANCING ARRANGEMENTS

 

OnFebruary 29, 2024, we entered into a $15,000 Senior Secured Revolving Line of Credit with Bank of America (the “Revolver”).The Revolver allows for borrowings at a defined base rate, or at the one, three or six month Secured Overnight Finance Rate, also knownas “SOFR,” plus a defined margin. If the Company prepays SOFR borrowings before their contractual maturity, the Company hasagreed to compensate the bank for lost margin, as defined in the Revolver agreement. The Company is required to quarterly pay a 20-basispoint fee on the unused portion of the Revolver.

 

TheRevolver requires the Company to maintain no more than 2.5 times leverage ratio and at least a 1.25 times minimum fixed charges coverageratio, both of which are defined in the Revolver agreement. These ratios are calculated based on trailing twelve-month results. Thereare no subjective acceleration clauses under the Revolver that would accelerate the maturity of outstanding borrowings. The Revolvercontains certain covenants which, among other things, require the Company to adhere to regular reporting requirements, abide by shareholderdividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The Revolver is securedby substantially all the Company’s assets and expires on February 28, 2027. We were not in compliance with financial covenantsrelated to the maximum operating expense contributions to our Mexican operations in the first and second quarters of 2024. We have receiveda waiver of this event of default from the bank. On March 27, 2025, we amended (the “First Amendment”) the Revolver to waiveour non-compliance with the leverage ratio and minimum fixed charge ratio as of December 31, 2024, and March 31, 2025. Provisions ofthe First Amendment relating to the Company’s compliance with these ratios were replaced with provisions of the Second Amendment(described below). Provisions of the First Amendment relating to minimum EBITDA requirements of the Company were replaced with provisionsof the Second Amendment (described below). Provisions of the First Amendment requiring the Company to maintain unrestricted cash andRevolver availability (collectively, “Liquidity”) at specified levels were replaced with provisions of the Second Amendment(described below). The First Amendment also requires the Company to provide incremental monthly reporting and increased the Company’sborrowing rate by one percent until the Company is in compliance with the original terms of the Revolver. The First Amendment increases the borrowing rate for revolving loans by 100 basis points.

 

OnMay 14, 2025, we further amended (the “Second Amendment”) the Revolver, which amended the First Amendment in part, todefer the Company’s compliance with the leverage ratio and minimum fixed charge ratio until the fourth quarter of 2025 at whichtime the Company must maintain (a) a leverage ratio of 2.5 times for the year ended December 31, 2025 and for each twelve-month quarterlyreporting period thereafter; and (b) a minimum fixed charge coverage ratio to 1.25 times for the year ended December 31, 2025 and foreach twelve-month quarterly reporting period thereafter. The Company must also maintain adjusted EBITDA (earnings before interest, taxesdepreciation and amortization), as defined in the Revolver, as of the end of the second quarter of 2025 of at least $1,000, the thirdquarter of 2025 of at least $1,300 and the fourth quarter of 2025 and each quarter thereafter of at least $1,600. In addition, the SecondAmendment requires the Company to always maintain Liquidity of at least $2,500. The Second Amendment shortened the duration of theRevolver to June 30, 2026 and increases the borrowing rate by 25 basis points.

 

OnJuly 29, 2025, we amended the Revolver (the “Third Amendment”) to extend the expiration of the Revolver to August 31, 2026.We have recorded the outstanding Revolver amount of $11,615 as long-term on the condensed consolidated balance sheets based on extensionin the signed Third Amendment.

 

TheRevolver, as amended, bears interest at a weighted-average interest rate of 7.8% and 7.7% as of June 30, 2025 and December 31, 2024,respectively. We had borrowings on our line of credit of $11,615 and $8,695 outstanding as of June 30, 2025 and December 31, 2024, respectively.As of June 30, 2025, we had unused availability on the line of credit of $3,385, which is subject to a month end cap based on the previouslynoted minimum Liquidity.

 

TheCompany had an interim funding agreement with a bank related to deposits made on equipment purchases funded through a finance lease whenthe equipment was received and operational. The equipment was received and the lease agreements were finalized during the three monthsended June 30, 2025. As of June 30, 2025, we have no amounts outstanding on the interim funding agreement for equipment.

 

11

 

 

NOTE5. LEASES

 

Wehave operating leases for certain manufacturing sites, office space, and equipment. Most leases include the option to renew, with renewalterms that can extend the lease term from one to five years or more. Right-of-use lease assets and lease liabilities are recognized atthe commencement date based on the present value of the remaining lease payments over the lease term which includes renewal periods weare reasonably certain to exercise. Our leases do not contain any material residual value guarantees or material restrictive covenants.As of June 30, 2025, we have no amounts outstanding on the interim funding agreement for equipment. We have financing leases for certain property and equipment used in the normal course of business.

 

Thecomponents of lease expense were as follows:

 

Lease Cost  2025   2024 
   Three Months Ended June 30, 
Lease Cost  2025   2024 
Operating lease cost  $564   $581 
Finance lease interest cost   9    6 
Finance lease amortization expense   33    129 
Total lease cost  $606   $716 

 

Lease Cost  2025   2024 
   Six Months Ended June 30, 
Lease Cost  2025   2024 
Operating lease cost  $1,129   $1,177 
Finance lease interest cost   15    12 
Finance lease amortization expense   85    129 
Total lease cost  $1,229   $1,318 

 

Supplementalcondensed consolidated balance sheet information related to leases was as follows:

 

   Balance Sheet Location 

June 30,

2025

  

December 31,

2024

 
Assets             
Finance lease assets  Property and equipment, net  $

878

   $411 
Operating lease assets  Operating lease assets, net   7,563    8,139 
Total leased assets     $

8,441

   $8,550 
              
Liabilities             
Current             
Current operating lease liabilities  Current portion of operating lease obligations  $1,237   $1,175 
Current finance lease liabilities  Current portion of finance lease obligations   229    143 
Noncurrent             
Long-term operating lease liabilities  Long-term operating lease obligations, net of current portion   7,145    7,773 
Long-term finance lease liabilities  Long-term finance lease obligations, net of current portion   781    311 
Total lease liabilities     $9,392   $9,402 

 

12

 

 

Supplementalcondensed consolidated statements of cash flows information for the six months ended June 30, 2025 and 2024 related to leases was asfollows:

  

   June 30,   June 30, 
   2025   2024 
Operating Leases          
Cash paid for amounts included in the measurement of lease liabilities  $880   $933 
Conversion of notes payable to finance leases   $637   $1,923 

 

Futureannual payments of lease liabilities as of June 30, 2025 were as follows:

  

  

Operating

Leases

  

Finance

Leases

   Total 
Remainder of 2025  $925   $144   $1,069 
2026   1,864    320    2,184 
2027   1,571    212    1,783 
2028   1,569    212    1,781 
2029   986    197    1,183 
Thereafter   4,669    67    4,736 
Total lease payments  $11,584   $1,152   $12,736 
Less: imputed interest   (3,202)   (142)   (3,344)
Present value of lease liabilities  $8,382   $1,010   $9,392 

 

Thelease term and discount rate as of June 30, 2025 and 2024 were as follows:

  

   June 30,
2025
  

June 30,

2024

 
Weighted-average remaining lease term (years)          
Operating leases   7.4    8.1 
Finance leases   2.0    1.7 
Weighted-average discount rate          
Operating leases   7.8%   8.0%
Finance leases   6.6%   5.3%

 

13

 

 

NOTE6. STOCK BASED AWARDS

 

Stock-basedcompensation expense of $117 and $126 for the three months ended June 30, 2025 and 2024, respectively, and $235 and $206 for the sixmonths ended June 30, 2025 and 2024, respectively, was reported in the condensed consolidated statements of operations within generaland administrative expenses.

 

StockOptions

 

Underthe 2017 Stock Incentive Plan (“2017 Plan”), as amended, there are an aggregate of 775,000 shares authorized for issuance.

 

Wegranted 43,382 service-based stock options during the three and six months ended June 30, 2025. We granted 22,000 service-based stockoptions during the three and six months ended June 30, 2024. Weighted average stock option fair value assumptions and the weighted averagegrant date fair value of stock options granted were as follows:

  

   2025   2024 
Stock option fair value assumptions:          
Risk-free interest rate   4.14%   4.40%
Expected life (years)   6.4    6.0 
Dividend yield   -%   -%
Expected volatility   58%   58%
Weighted average grant date fair value of stock options granted  $5.21   $6.47 

 

Totalcompensation expense related to stock options was $69 and $123 for the three and six months ended June 30, 2025, respectively. Totalcompensation expense related to stock options was $65 and $121 for the three and six months ended June 30, 2024, respectively. As ofJune 30, 2025, there was $764 of unrecognized compensation related to stock options which will be recognized over a weighted averageperiod of 2.66 years.

 

Followingis a summary of stock option activity as of and for the six months ended June 30, 2025 and 2024:

  

   Shares  

Weighted-

Average

Exercise Price

Per Share

  

Weighted-

Average

Remaining

Contractual

Term
(in years)

  

Aggregate

Intrinsic Value

 
Outstanding – December 31, 2023   458,700   $6.63    6.53   $1,432 
Granted   22,000    11.06           
Exercised   (5,500)   5.42           
Forfeited   (9,600)   10.26           
Outstanding – June 30, 2024   465,600   $6.78    6.20   $3,150 
                     
Outstanding – December 31, 2024   453,400   $6.79    5.70   $1,654 
Granted   43,382    8.73           
Exercised   (1,200)   3.98           
Forfeited   (9,800)   9.66           
Outstanding – June 30, 2025   485,782   $6.92    5.60   $1,213 
Exercisable on June 30, 2025   305,000   $5.28    4.10   $1,198 

 

RestrictedStock Units

 

Totalcompensation expense related to restricted stock units (“RSUs”) was $48 and $112 for the three and six months ended June30, 2025, respectively. Total compensation expense related to RSUs was $61 and $85 for the three and six months ended June 30, 2024,respectively. During the three- and six-month periods ended June 30, 2025 and 2024, we granted 43,664 and 15,141RSUs, respectively, at an average grant price per share of $8.73 and $11.06, respectively, under our 2017 Stock Incentive Planto non-employee directors which vest over two years. As of June 30, 2025, total unrecognized compensation expense related tothe RSUs was $356, which will vest over a weighted average period of 1.8 years.

 

Followingis a summary of RSU activity as of and for the six months ended June 30, 2025 and 2024:

  

   Shares  

Weighted-

Average

Remaining

Vesting

Term
(in years)

  

Aggregate

Intrinsic Value

 
Outstanding – December 31, 2023   27,000    1.0   $254 
Granted   15,141           
Vested   (16,500)          
Forfeited   (1,500)          
Outstanding – June 30, 2024   24,141    0.9   $330 
                
Outstanding – December 31, 2024   24,141    0.3   $248 
Granted   43,664           
Vested   (24,141)          
Forfeited   -           
Outstanding – June 30, 2025   43,664    1.9   $63 

 

14

 

 

NOTE7. NET INCOME (LOSS) PER SHARE DATA

 

Basicnet income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding.Dilutive net income (loss) per common share assumes the exercise and issuance of all potential common stock equivalents in computingthe weighted-average number of common shares outstanding using the treasury stock method, unless their effect is anti-dilutive. Basicand diluted weighted average shares outstanding were as follows:

  

   2025   2024   2025   2024 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2025   2024   2025   2024 
Basic weighted average shares outstanding   2,773,598    2,760,052    2,767,263    2,751,330 
Dilutive effect of outstanding stock options and non-vested restricted stock units1   181,167    175,619    -    170,783 
Diluted weighted average shares outstanding   2,954,765    2,935,671    2,767,263    2,922,113 

 

1

The following items were excluded from the computation of diluted weighted-average shares outstanding as their inclusion would be anti-dilutive:

 

 a.For the three and six months ended June 30, 2025, restricted stock units and stock options totaling 89,927 and 504,194, respectively.
 b.For the three and six months ended June 30, 2024, restricted stock units and stock options totaling 31,611 and 45,453, respectively.

 

NOTE8. INCOME TAXES

 

Ona quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provisionbased on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discreteevents.

 

15

 

 

Oureffective tax rate for the three and six months ended June 30, 2025 was 35% and 25%, respectively. Our effective tax rate for thethree and six months ended June 30, 2024 was 12% and 21%, respectively. The primary drivers of the increase in effective tax rate werechanges in pretax (loss) income and taxes on foreign entities.

 

NOTE9. SEGMENT INFORMATION

 

Ourresults of operations for the six months ended June 30, 2025 and 2024 represent a single operating and reporting segment referred toas Contract Manufacturing within the EMS industry. The Company operates in the Medical Device, Medical Imaging, Aerospace and Defense,and Industrial markets with over 50% of its net sales coming from the medical-related markets. We strategically direct production betweenour various manufacturing facilities based on a number of considerations to best meet our customers’ needs. Our plants generatenet sales over several of the markets the Company serves. We share resources for sales, marketing, engineering, supply chain, informationservices, human resources, payroll, and all corporate accounting functions. Our chief operating decision maker (the “CODM”)is the Company’s President and Chief Executive Officer. The CODM regularly evaluates financial information prepared in accordancewith U.S. GAAP on a consolidated basis to assess performance and allocate resources.

 

TheCompany’s net sales were located as follows:

 

   2025   2024   2025   2024 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2025   2024   2025   2024 
United States  $18,005   $22,480   $34,315   $46,009 
Mexico   7,895    7,571    14,475    14,357 
China   4,775    3,840    8,780    7,740 
Total net sales  $30,675   $33,891   $57,570   $68,106 

 

TheCompany’s long-lived tangible assets, including the Company’s operating lease assets recognized on the condensed consolidatedbalance sheets were located as follows:

  

  

June 30,

2025

  

December 31,

2024

 
United States  $9,326   $10,429 
Mexico   2,195    2,445 
China   1,485    1,497 
Total long-lived tangible assets  $13,006   $14,371 

 

NOTE10. RESTRUCTURING CHARGES

 

During2024, we recorded restructuring charges of $571related to the closure and consolidation of our Blue Earth, Minnesota production facility, which was completed in the fourth quarterof 2024. During the six months ended June 30, 2025, the Company incurred $266of restructuring charges, in connection with activities related to the Blue Earth facility and additional staff reductions in thefirst quarter of 2025. We have not recorded any restructuring charges in the three months ended June 30, 2025.

 

Thefollowing table summarizes the related activity for the six months ended June 30, 2025:

 

   Facility Consolidation   Workforce Reductions   Total 
             
December 31, 2024  $         154   $            -   $154 
Charges   31    235    266 
Cash payments   (185)   (235)   (420)
June 30, 2025  $-   $-   $- 

 

16

 

 

Thefollowing table summarizes the related activity for the six months ended June 30, 2024:

 

   Facility Consolidation 
     
December 31, 2023  $                    - 
Charges   91 
Cash payments   - 
June 30, 2024  $91 

 

NOTE11. RELATED PARTY TRANSACTIONS

 

DavidKunin, our Chairman, is a minority owner of Abilitech Medical, Inc. We had accounts receivable related to Abilitech of $226 as of December31, 2023. Payments of $33 were received during the year ended December 31, 2024 and we wrote off the remaining receivables during 2024.Abilitech has ceased operations and therefore we do not believe that Abilitech will pay the Company for outstanding accounts receivable.The Company believes that transactions with Abilitech were on terms comparable to those that the Company could reasonably expect in anarm’s length transaction with an unrelated third party.

 

DavidKunin, our Chairman, is a minority owner (less than 10%) of Marpe Technologies, LTD an early-stage medical device company dedicated tothe early detection of skin cancer through full body scanners. Mr. Kunin is also a member of the Board of Directors of Marpe Technologies.The Company worked with Marpe Technologies to apply for a grant from the Israel-United States Binational Industrial Research and DevelopmentFoundation, a legal entity created by Agreement between the Government of the State of Israel and the Government of the United Statesof America (“BIRD Foundation”). The parties were successful in receiving approval for a $1,000 conditional grant. The Companyand Marpe Technologies will each receive $500 from the BIRD Foundation and, among other obligations under the grant, each is requiredto contribute $500 to match grant funds from the BIRD Foundation. The Company met its obligation by providing certain services at costor with respect to administrative services at no cost to Marpe Technologies. The total value of the Company’s contribution willnot exceed $500. Marpe is engaged in raising funds for its operations, which funds are necessary to pay for the Company’s servicesbeyond its contribution. The Company will receive a 10-year exclusive right to manufacture the products of Marpe Technologies. Therecan be no assurances that Marpe Technologies’ medical device operations will be commercially successful, that Marpe Technologieswill be successful in raising additional funds to finance its operations or, if commercially successful, the Company will recover thevalue of services provided to Marpe if not paid when the services are provided. The transactions between the Company and Marpe Technologieshave been approved by the Audit Committee pursuant to the Company Related-Party Transactions Policy. During the three and six monthsended June 30, 2025 and 2024, we recognized no net sales to Marpe Technologies. As of June 30, 2025, we have no outstanding accountsreceivable. The Company believes that transactions with Marpe are on terms comparable to those that the Company could reasonably expectin an arm’s length transaction with an unrelated third party.

 

NOTE12. SUBSEQUENT EVENTS

 

OnJuly 24, 2025, the Company closed on the sale of the Blue Earth facility for $500 as discussed in Note 1 – “Summary of SignificantAccounting Policies.”

 

OnJuly 29, 2025, the Company amended its Revolver line of credit agreement as discussed in Note 4 – “Financing Arrangements.”

 

17

 

 

ITEM2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

Weare a Minnesota, United States based full-service global EMS contract manufacturer in the Medical Device, Medical Imaging, Aerospaceand Defense and Industrial markets offering a full range of value-added engineering, technical and manufacturing services and supportincluding project management, design, testing, prototyping, manufacturing, supply chain management and post-market services. Our productsare complex electromedical and electromechanical products including medical devices, wire and cable assemblies, printed circuit boardassemblies, complex higher-level assemblies and other box builds for a wide range of industries. As of December 31, 2024, we have facilitiesin Minnesota: Bemidji, Mankato, Milaca and Maple Grove. We closed our facility in Blue Earth, Minnesota in December 2024 and sold thisfacility on July 24, 2025. We also have facilities in Monterrey, Mexico and Suzhou, China.

 

Ournet sales are derived from complex designed products built to the customers’ specifications. The products we manufacture are engineeredand designed products that require sophisticated manufacturing support. Quality, on-time delivery, and reliability are of utmost importance.Our goal is to expand and diversify our customer base by focusing on sales and marketing efforts that fit our value-added service, earlyengagement design, and development strategy. We continue to focus on lean manufacturing initiatives, quality and on-time delivery improvementsto increase asset utilization, reduce lead times and provide competitive pricing.

 

Ourstrategic investments have positioned us to capitalize on growth opportunities in the medical markets and improve our competitivenessby expanding our global footprint. Our industrial and defense markets are focused on improving our asset utilization and profitabilitywhile transforming to a value added, solution-sell business model that supports early engagement, design for manufacturability and rapidprototyping.

 

Alldollar amounts are stated in thousands of U.S. dollars.

 

RestructuringActivities

 

Infiscal year 2024, the Company initiated a restructuring plan related to the closure of its Blue Earth, MN facility. During the threeand six months ended June 30, 2025, the Company incurred restructuring charges related to staff reductions and activities related tothe Blue Earth facility closure. The costs of these restructuring programs totaled $837, of which $266 was recorded in the six monthsended June 30, 2025 and $571 was recorded in the prior fiscal year. We did not record any amounts related to restructuring in the three monthsended June 30, 2025. These costs are included in restructuring charges on the condensedconsolidated statements of operations. These charges relate to employee severance and facility closure costs. We do not expect significantadditional expenses related to this plan.

 

Resultsof Operations

 

NetSales. Net sales for the three months ended June 30, 2025 and 2024 were $30,675 and $33,891, respectively, a comparative period decreaseof $3,216 or 9.5%. Net sales for the six months ended June 30, 2025 and 2024 were $57,570 and $68,106, respectively, a comparative perioddecrease of $10,536 or 15.5%. Net sales in the three and six months ended June 30, 2025 were negatively impacted by delays in Aerospaceand Defense customer approvals of products transferred from our Blue Earth facility to our Bemidji facility as well as manufacturingand plant utilization inefficiencies related to the movement of various production between plants. The following is a summary of net sales by our major industry markets:

 

   Three Months Ended June 30,     
   2025   2024   Increase (Decrease) 
Medical Device  $7,550   $9,689   $(2,139)   (22.1)%
Medical Imaging   9,664    8,182    1,482    18.1%
Industrial   8,516    9,385    (869)   (9.3)%
Aerospace and Defense   4,945    6,635    (1,690)   (25.5)%
Total net sales  $30,675   $33,891   $(3,216)   (9.5)%

 

18

 

 

   Six Months Ended June 30,     
   2025   2024   Increase (Decrease) 
Medical Device  $15,620   $19,893   $(4,273)   (21.5)%
Medical Imaging   18,252    17,083    1,169    6.8%
Industrial   15,461    18,977    (3,516)   (18.5)%
Aerospace and Defense   8,237    12,153    (3,916)   (32.2)%
Total net sales  $57,570   $68,106   $(10,536)   (15.5)%

 

  Medical Device: Net sales to our medical customers decreased $2,139, or 22.1%, in the three months ended June 30, 2025 as compared with the same period in 2024 and $4,273, or 21.5%, in the six months ended June 30, 2025 as compared with the same period in 2024. The decrease was primarily due to inventory re-balancing with existing customers, timing of customer product launches and lower productivity as we managed our facility consolidation.
     
  Medical Imaging: Net sales to our Medical Imaging customers increased $1,482, or 18.1%, in the three months ended June 30, 2025 as compared with the same period in 2024 and $1,169, or 6.8%, in the six months ended June 30, 2025 as compared with the same period in 2024. The increase was primarily due to higher sales to existing customers.
     
  Industrial: Net sales to our industrial customers decreased $869, or 9.3%, in the three months ended June 30, 2025 as compared with the same period in 2024 and $3,516, or 18.5%, in the six months ended June 30, 2025 as compared with the same period in 2024. The decrease in net sales was primarily due to customer order delays and part shortages.
     
  Aerospace and Defense: Net sales to our aerospace and defense customers decreased $1,690, or 25.5%, in the three months ended June 30, 2025 as compared with the same period in 2024 and $3,916, or 32.2%, in the six months ended June 30, 2025 as compared with the same period in 2024. The decrease in net sales relates to delays in customer approvals as we have consolidated this business into our Bemidji facility.

 

Backlog.Our 90-day shipment backlog as of June 30, 2025 was $26,592, a decrease of 0.6% from $26,742 at the beginning of the quarter, andan 11.6% decrease from June 30, 2024. Our 90-day backlog consists of firm purchase orders we expect to ship in the next 90 days, withany remaining amounts to be shipped within 180 days.

 

Ourtotal order backlog as of June 30, 2025, was $78,351, representing a 14.7% increase from $68,332 at the beginning of the quarter anda 6.9% increase compared to the same period in the prior year; this growth was primarily driven by large medical device orders.

 

90-dayshipment and total backlog by our major industry markets are as follows:

 

   June 30, 2025   March 31, 2025   June 30, 2024 
   90 Day   Total   90 Day   Total   90 Day   Total 
Medical Device  $7,897   $32,222   $5,735   $19,925   $8,130   $23,497 
Medical Imaging   5,101    7,584    7,526    10,020    7,776    10,953 
Industrial   6,010    9,349    5,999    10,005    6,398    11,423 
Aerospace and Defense   7,584    29,196    7,482    28,382    7,791    27,423 
Total backlog  $26,592   $78,351   $26,742   $68,332   $30,095   $73,296 

 

19

 

 

The90-day and total backlog as of June 30, 2025 includes orders already recognized in net sales and included in the contract asset valueof $14,984.

 

OperatingCosts and Expenses.

 

Netsales, cost of goods sold, gross profit, and operating costs were as follows:

 

   Three Months Ended June 30, 
   2025   2024   Increase/(Decrease) 
Net sales  $30,675   $33,891   $(3,216

)

   (9.5)%
Cost of goods sold (3)   25,838    29,274    (3,436

)

   (11.7)%
Gross profit   4,837    4,617    220     4.8%
Gross margin percentage (1)   15.8%   13.6%   220 bpc(2)     
Selling (3)   1,204    909    295     32.5%
% of Net sales   3.9%   2.7%           
General and administrative   2,589    2,982    (393 )   (13.2)%
% of Net sales   8.4%   8.8%           
Research and development   302    291    11     3.8%
% of Net sales   1.0%   0.9%           
Restructuring charges -    91    (91    (100)%
% of Net sales -%   0.2%           
Operating income   742    344    

398

    

115.7

%
% of Net sales   2.4%   1.0%           

 

  (1) Gross margin percentage is defined as gross profit as a percentage of net sales.
  (2) Basis points change in gross margin percentage.
  (3) During the first quarter of 2025, the Company modified the responsibilities and reporting relationships of certain customer-facing managers. As a result of these organizational changes, the related costs, which were previously classified as cost of sales, are now reported as selling expenses to better reflect the nature of the activities performed.

 

    Six Months Ended June 30,  
    2025     2024     Increase/(Decrease)  
Net sales   $ 57,570     $ 68,106     $ (10,536     (15.5 )%
Cost of goods sold (3)     49,655       58,041       (8,386     (14.4 )%
Gross profit     7,915       10,065       (2,150     (21.4 )%
Gross margin percentage (1)     13.7 %     14.8 %     (110 )bpc(2)        
Selling (3)     2,388       1,714       674       39.3 %
% of Net sales     4.1 %     2.5 %                
General and administrative     5,504       6,152       (648 )     (10.5 )%
% of Net sales     9.6 %     9.0 %                
Research and development     628       609       19       3.1 %
% of Net sales     1.1 %     0.9 %                
Restructuring charges     266       91       175       192.3 %
% of Net sales     0.5 %     0.2 %                
Operating (loss) income     (871 )     1,499       (2,370 )     (158.1 )%
% of Net sales     (1.5 )%     2.3 %                

 

  (1) Gross margin percentage is defined as gross profit as a percentage of net sales.
  (2) Basis points change in gross margin percentage.
  (3) During the first quarter of 2025, the Company modified the responsibilities and reporting relationships of certain customer-facing managers. As a result of these organizational changes, the related costs, which were previously classified as cost of sales, are now reported as selling expenses to better reflect the nature of the activities performed.

 

Grossprofit and gross margins. Gross profit as a percent of net sales was 15.8% and 13.6% for the three months ended June 30, 2025,and 2024, respectively. Gross profit as a percent of net sales was 13.7% and 14.8% for the six months ended June 30, 2025, and 2024,respectively. The increase in gross profit as a percentage of net sales in the quarterly comparison period was the result ofimproved plant utilization and favorable sales mix. The decrease in gross profit as a percentage of net sales in the year-to-datecomparison period was the result of lower net sales and reduced facility utilization in the first three months of this year as wellas reduced manufacturing efficiencies due to customer program movements between facilities.

 

20

 

 

Sellingexpenses. Selling expenses, as measured as a percent of net sales, was 3.9% and 2.7% for the three months ended June 30, 2025,and 2024, respectively. Selling expenses, as measured as a percent of net sales, was 4.1% and 2.5% for the six months ended June30, 2025, and 2024, respectively. In 2025, we realigned the reporting structure of our customer facing managers from operations to businessdevelopment. As a result, this increase is a result of the realignment as well as the impact of fixed costs on a lower revenue base.

 

General and administrative expenses.General and administrative expenses, as measured as a percent of net sales, was 8.4% and 8.8% for the three months ended June 30,2025 and 2024, respectively, and 9.6% and 9.0% for the six months ended June 30, 2025 and 2024, respectively. General andadministrative expenses decreased in the quarterly and year to date 2025 periods by $393 and $648, respectively, as compared withthe 2024 periods primarily as the result of lower incentive compensation accruals in the current year.

 

Restructuring charges. Restructuring chargeswere $0 and $266 in the three and six months ended June 30, 2025, respectively. During the first quarter of 2025, we incurred $235 of severance charges for a February 2025 reductionin force to align staffing to our forecasted net sales and $31 of expenses related to our closed Blue Earth facility. Restructuring chargeswere $91 in the three and six months ended June 30, 2024 for accrued employee retention bonuses for our facility consolidation and closureof our Blue Earth facility.

 

Operating (loss) income. Operating incomewas $742 for the three months ended June 30, 2025 or 2.4% of net sales and was $344 or 1.0% of net sales for the three months endedJune 30, 2024. This increase was driven by the improved gross margin and lower incentive compensation expense. Operating loss was ($871) or (1.5)% of net sales for the sixmonths ended June 30, 2025 and operating income was $1,499 or 2.3% of net sales for the six months ended June 30, 2024. The decreasewas driven by the decrease in net sales and resulting gross margin.

 

Interestexpense. Interest expense was $257 and $165 for the three months ended June 30, 2025 and 2024, respectively. Interest expense was$471 and $332 for the six months ended June 30, 2025 and 2024, respectively. This increase was driven by higher borrowings under ourline of credit arrangement. Refer to “Liquidity and Capital Resources” for further discussion of financing arrangements.

 

Income taxes. Our effective tax rate for thethree and six months ended June 30, 2025 was 35% and 25%. Our effective tax rate for the three and six months ended June 30, 2024 was12% and 21%. The primary drivers of the increase in effective tax rate were changes in pretax (loss) income and taxes on foreign entities.

 

In July 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted. The OBBBA makes permanent key elementsof the Tax Cuts and Jobs Act of 2017, including 100% bonus depreciation, domestic research cost expensing and the business interest expenselimitation, among other tax changes. The new legislation has multiple effective dates, with certain provisions effective in 2025 and othersin the future. The Company is currently evaluating the provisions of the new law and the potential effects on the Company’s financialposition, results of operations, and cash flows.

 

CashFlow Operating Results

 

Thefollowing is a summary of cash flow results:

 

    Six Months Ended June 30,  
    2025     2024  
Cash provided by (used in):                
Operating activities   $ (2,773 )   $ (1,458 )
Investing activities     (358 )     (1,011 )
Financing activities     2,858       2,343  
Effect of exchange rates on changes in cash and cash equivalents     9       (7 )
Net change in cash and cash equivalents   $ (264 )   $ (133 )

 

Operating Activities. Cash used in operatingactivities was $2,773 in the first six months of 2025, compared with $1,458 in the same prior-year period. Significant changes in operatingassets and liabilities affecting cash flows during these periods included:

 

  Cash used by accounts receivable and contract assets was $4,034 in the six months ended June 30, 2025 as compared with cash provided of $1,214 in the same prior-year period. The use of cash in the six months ended June 30, 2025 is largely due to timing of customer shipments and cash collections. The cash provided in the prior year was due an expected increase in cash collections due to higher sales and the timing of customer payments.
  Cash provided by inventory was $2,714 in the six months ended June 30, 2025 as compared with cash used of $1,288 in the prior-year period. The decrease in the current-year period cash usage was the result of normal timing variances of inventory purchases and timing of product shipments as well as the results of our plan to reduce inventory balances in 2025.

 

21

 

 

InvestingActivities. Cash used in investing activities was $358 in the first six months of 2025, compared with cash used of $1,011 in thesame prior-year period, both primarily for capital expenditures.

 

FinancingActivities. Cash provided by financing activities was $2,858 in the first six months of 2025 and $2,343 in the same prior-year period.The cash provided by financing activities in both periods resulted from the line of credit advances for working capital and operations.

 

Liquidityand Capital Resources

 

Webelieve that our existing financing arrangements, anticipated cash flows from operations and cash on hand will be sufficient to satisfyour working capital needs, capital expenditures and debt repayments for the next twelve months.

 

OnFebruary 29, 2024, we entered into a $15,000 Senior Secured Revolving Line of Credit with Bank of America (the “Revolver”).The Revolver allows for borrowings at a defined base rate, or at the one, three or six month Secured Overnight Finance Rate, also knownas “SOFR,” plus a defined margin. If the Company prepays SOFR borrowings before their contractual maturity, the Company hasagreed to compensate the bank for lost margin, as defined in the Revolver agreement. The Company is required to quarterly pay a 20-basispoint fee on the unused portion of the Revolver.

 

TheRevolver requires the Company to maintain no more than 2.5 times leverage ratio and at least a 1.25 times minimum fixed charges coverageratio, both of which are defined in the Revolver agreement. These ratios are calculated based on trailing twelve-month results. Thereare no subjective acceleration clauses under the Revolver that would accelerate the maturity of outstanding borrowings. The Revolvercontains certain covenants which, among other things, require the Company to adhere to regular reporting requirements, abide by shareholderdividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The Revolver is securedby substantially all the Company’s assets and expires on February 28, 2027. We were not in compliance with financial covenantsrelated to the maximum operating expense contributions to our Mexican operations in the first and second quarters of 2024. We have receiveda waiver of this event of default from the bank. On March 27, 2025, we amended (the “First Amendment”) the Revolver to waiveour non-compliance with the leverage ratio and minimum fixed charge ratio as of December 31, 2024, and March 31, 2025. Provisions ofthe First Amendment relating to the Company’s compliance with these ratios were replaced with provisions of the Second Amendment(described below). Provisions of the First Amendment relating to minimum EBITDA requirements of the Company were replaced with provisionsof the Second Amendment (described below). Provisions of the First Amendment requiring the Company to maintain unrestricted cash andRevolver availability (collectively, “Liquidity”) at specified levels were replaced with provisions of the Second Amendment(described below). The First Amendment also requires the Company to provide incremental monthly reporting and increased the Company’sborrowing rate by one percent until the Company is in compliance with the original terms of the Revolver. The First Amendment increases the borrowing rate for revolving loans by 100 basis points.

 

OnMay 14, 2025, we further amended (the “Second Amendment”) the Revolver, which amended the First Amendment in part, todefer the Company’s compliance with the leverage ratio and minimum fixed charge ratio until the fourth quarter of 2025 at whichtime the Company must maintain (a) a leverage ratio of 2.5 times for the year ended December 31, 2025 and for each twelve-month quarterlyreporting period thereafter; and (b) a minimum fixed charge coverage ratio to 1.25 times for the year ended December 31, 2025 and foreach twelve-month quarterly reporting period thereafter. The Company must also maintain adjusted EBITDA (earnings before interest, taxesdepreciation and amortization), as defined in the Revolver, as of the end of the second quarter of 2025 of at least $1,000, the thirdquarter of 2025 of at least $1,300 and the fourth quarter of 2025 and each quarter thereafter of at least $1,600. In addition, the SecondAmendment requires the Company to always maintain Liquidity of at least $2,500. The Second Amendment shortened the duration of theRevolver to June 30, 2026 and increases the borrowing rate by 25 basis points.

 

22

 

 

On July 29, 2025, we amendedthe Revolver (the “Third Amendment”) to extend the expiration of the Revolver to August 31, 2026. We have recorded the outstandingRevolver amount of $11,615 as long term on the condensed consolidated balance sheets based on extension in the signed Third Amendment.

 

The Revolver, as amended, bears interest at a weighted-average interestrate of 7.8% and 7.7% as of June 30, 2025 and December 31, 2024, respectively. We had borrowings on our line of credit of $11,615 and$8,695 outstanding as of June 30, 2025 and December 31, 2024, respectively. As of June 30, 2025, we had unused availability on the lineof credit of $3,385, which is subject to a month end cap based on the previously noted minimum Liquidity.

 

TheCompany had an interim funding agreement with a bank related to deposits made on equipment purchases funded through a finance lease whenthe equipment was received and operational. The equipment was received and the lease agreements were finalized during the three monthsended June 30, 2025. As of June 30, 2025, we have no amounts outstanding on the interim funding agreement for equipment.

 

Netsales in the first two quarters of 2025 and fourth quarter of 2024 were negatively impacted by delays in Aerospace and Defense customerapprovals of products transferred from our Blue Earth facility to our Bemidji facility as well as manufacturing and plant utilizationinefficiencies related to the movement of various production between plants. We expect these matters to be resolved over the next twoquarters. The Company has implemented plant optimization activities and cost cutting initiatives in the first two quarters of 2025 toaddress losses. These actions plus continued efforts to improve manufacturing efficiencies in the remainder of 2025 and the planned reductionin inventory levels are intended to drive reduced borrowings during the remainder of 2025. The Company believes it has sufficient capitaland liquidity to operate its business for at least twelve months from the filing of this Form 10-Q.

 

Off-BalanceSheet Arrangements

 

Wehave not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

 

Forward-LookingStatements

 

Thosestatements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisionsof the Private Securities Litigation Reform Act of 1995.

 

  Volatility in the marketplace which may affect market supply, demand of our products or currency exchange rates;
  Whether our existing financing arrangements, anticipated cash flows from operations and cash on hand will be sufficientto satisfy our working capital needs, capital expenditures and debt repayments for the next twelve months;
  Supply chain disruption and unreliability;
  Lack of supply of sufficient human resources to produce our products;
  Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;
  Changes in the reliability and efficiency of our operating facilities or those of third parties;
  Increases in certain raw material costs such as copper and oil;
  Commodity and energy cost instability;
  Risks related to FDA noncompliance;
  The loss of a major customer;
  General economic, financial and business conditions that could affect our financial condition and results of operations;
  Increased or unanticipated costs related to compliance with securities and environmental regulation;
  Disruption of global or local information management systems due to natural disaster or cyber-security incident; and

 

23

 

 

  Outbreaks of epidemic, pandemic, or contagious diseases, such as the recent novel coronavirus that affect our operations, our customers’ operations or our suppliers’ operations.

 

Thefactors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actualresults to differ materially from those expressed in any forward-looking statement made by us. Unpredictable or unknown factors not discussedherein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-Qare expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligation to update publicly any forward-lookingstatement (or its associated cautionary language) whether as a result of new information or future events.

 

Pleaserefer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December31, 2024.

 

ITEM3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Notapplicable.

 

ITEM4. CONTROLS AND PROCEDURES

 

Evaluationof Disclosure Controls and Procedures

 

Inaccordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period coveredby this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief FinancialOfficer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed inthe Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulatedand communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, toallow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of thedate of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedureswere effective.

 

Changesin Internal Control Over Financial Reporting

 

Therewas no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

24

 

 

PARTII

 

ITEM1. LEGAL PROCEEDINGS

 

Weare subject to various legal proceedings and claims that arise in the ordinary course of business.

 

ITEM1A. RISK FACTORS

 

Weare affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significantfactors known to us that could materially adversely affect our business, financial condition or operating results or could cause ouractual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended underthe heading “Part I – Item 1A.Risk Factors.” There have been no material changes in the risk factors from those disclosedin the Annual Report on Form 10-K for the year ended December 31, 2024, except as set forth below.

 

If we fail to comply with the covenants containedin our credit agreement, we may be unable to secure additional financing and repayment obligations on our outstanding indebtedness maybe accelerated.

 

Our credit agreement contains financial and operatingcovenants with which we must comply. Effective as of February 29, 2024, we entered into a new credit agreement with Bank of America (the“Revolver”.) Our Revolver contains financial and operating covenants with which we must comply. Our compliance with thesecovenants is dependent on our financial results, which are subject to fluctuation as described elsewhere in these risk factors. We werenot in compliance with financial covenants related to the maximum operating expense contributions to our Mexican operations in the firstand second quarters of 2024. We received a waiver of the Mexican operating expenses event of default from the bank in August 2024.

 

On March 27, 2025, we signed the First Amendment tothe Revolver to waive the leverage ratio and minimum charge coverage ratio events of default as of December 31, 2024 and March 31, 2025and to further defer the Company’s compliance with these ratios until the third quarter of 2025, and reset compliance thresholdsfor our covenant ratios for 2025. The First Amendment also set minimum EBITDA levels for the second, third and fourth quarters and increasedthe borrowing rate by 100 basis points. On May 14, 2025, we signed the Second Amendment to the Revolver to defer the Company’s compliancewith the leverage ratio and minimum charge coverage ratio until the fourth quarter. The Second Amendment also modified downward the minimumEBITDA levels for the second, third and fourth quarters and shortened the duration of the Revolver to June 30, 2026 and further increasedthe borrowing rate by 25 basis points. On July 29, 2025, we signed the Third Amendment to the Revolver delaying expiration of the Revolverto August 31, 2026.

 

We have included the Amendment No. 1 to Credit Agreement,Waiver, and Consent, Amendment No. 2 to Credit Agreement and Amendment No. 3 to Credit Agreement as exhibits to this filing and any descriptionof that document contained in this risk factor is only a summary and is qualified by its entirety by the filed documents. If we failto comply with the covenants in the future or if our lender does not agree to waive any future non-compliance, we may be unable to borrowfunds and any outstanding indebtedness could become immediately due and payable, which could materially harm our business. 

 

Impairment of Our Long-Lived Assets CouldAdversely Affect Our Results of Operations and Financial Condition.

 

We evaluate long-lived assets, primarily propertyand equipment, whenever current events or changes in circumstances indicate that the carrying amount of an asset or asset group may notbe recoverable. Recoverability for assets to be held and used is based on our projection of the undiscounted future operating cash flowsof the underlying assets. To the extent such projections indicate that future undiscounted cash flows are not sufficient to recover thecarrying amounts of related assets, a charge might be required to reduce the carrying amount to equal estimated fair value.

 

As of June 30, 2025, the Company’s common stock was trading ata value less than the Company’s net equity value. As such, the Company evaluated future undiscounted cash flows and determined thatno long-lived asset impairment was required as of June 30, 2025. If the fair value of our other long-lived assets is less than their carryingvalue, we may be required to record a non-cash impairment charge, which could be material. Such charges could negatively impact our resultsof operations, potentially affect our compliance with debt covenants, and reduce the perceived value of our Company. There can be no assurancethat future reviews of long-lived assets will not result in impairment charges, particularly in periods of market or economic volatility.

 

ITEM2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM3. DEFAULTS ON SENIOR SECURITIES

 

None.

 

ITEM4. MINE SAFETY DISCLOSURES

 

Notapplicable.

 

ITEM5. OTHER INFORMATION

 

None.

 

ITEM6. EXHIBITS

 

Exhibits    
     
31.1*   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
     
31.2*   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
     
32*   Certification of the Chief Executive Officer and Chief Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101*   Financial statements from the quarterly report on Form 10-Q for the quarter ended June 30, 2025, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Condensed Consolidated Statements of Cash Flows, and (iv) the Notes to Condensed Consolidated Financial Statements.
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

*Filedherewith

 

25

 

 

Signatures

 

Pursuantto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf bythe undersigned, thereunto duly authorized.

 

  Nortech Systems Incorporated and Subsidiaries
   
Date: August 7, 2025 by /s/ Jay D. Miller
    Jay D. Miller
    Chief Executive Officer and President
    Nortech Systems Incorporated
     
Date: August 7, 2025 by /s/ Andrew D. C. LaFrence
    Andrew D. C. LaFrence
    Chief Financial Officer and Senior Vice President of Finance
    Nortech Systems Incorporated

 

26

 

 

Exhibit31.1

 

Certificationof Chief Executive Officer

Pursuantto Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I,Jay D. Miller, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Nortech Systems Incorporated and Subsidiaries;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2025 By: /s/ Jay D. Miller
    Jay D. Miller
    Chief Executive Officer and President
    Nortech Systems Incorporated

 

   

 

 

Exhibit31.2

 

Certificationof Chief Financial Officer

Pursuantto Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

 

I,Andrew D. C. LaFrence, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Nortech Systems Incorporated. and Subsidiaries;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2025 By: /s/ Andrew D. C. LaFrence
    Andrew D. C. LaFrence
    Chief Financial Officer and Senior Vice President of Finance
    Nortech Systems Incorporated

 

   

 

 

Exhibit32

 

WrittenStatement of the Chief Executive Officer

Pursuantto 18 U.S.C. Section 1350

 

Solelyfor the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Jay D. Miller, hereby certify, based on my knowledge, thatthe Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2025 (the “Report”) fully complies with therequirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, inall material respects, the financial condition and results of operations of the Company.

 

Date:August 7, 2025

 

By: /s/ Jay D. Miller  
  Jay D. Miller  
  Chief Executive Officer and President  
  Nortech Systems Incorporated  

 

 

 

 

WrittenStatement of the Chief Financial Officer

Pursuantto 18 U.S.C. Section 1350

 

Solelyfor the purposes of complying with 18 U.S.C. Section 1350, I, the undersigned Andrew D .C. LaFrence, hereby certify, based on my knowledge,that the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2025 (the “Report”) fully complies withthe requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents,in all material respects, the financial condition and results of operations of the Company.

 

Date:August 7, 2025

 

By: /s/ Andrew D. C. LaFrence  
  Andrew D. C. LaFrence  
  Chief Financial Officer and Senior Vice President of Finance  
  Nortech Systems Incorporated